EASD 2026: Orforglipron shows an efficacy edge over oral semaglutide in T2D

ConferencepositiveOrforglipronSemaglutidePositive

AI Analysis

Summary

Orforglipron demonstrated modestly superior weight and HbA1c reductions compared to oral semaglutide in type 2 diabetes, supporting its therapeutic potential. The data was presented at EASD 2026.

Outcome Details

Orforglipron demonstrated modestly greater weight and HbA1c reductions compared to oral semaglutide

Importance:6/10

Sentiment:

0.65

Type 2 DiabetesGLP-1 AgonistComparative EfficacyEASD 2026Clinical Data

Related Companies

$GCAN

Read the original article

Published by Pharmaceutical Technology on September 29, 2026 7:24 PM

Read Original